Diagnosed prevalent cases of Nontuberculous Mycobacteria (NTM) infections are expected to increase in the US, the UK, and Japan by 0.88% between 2021 and 2031.

Treatment regimens for NTM are a combination therapy of at least three different antibiotics, frequently including macrolides.

The greatest unmet needs within the NTM market are new antibiotics with improved success rates and minimal toxicity.

The late stage NTM pipeline consists of seven drugs, six of which are first in class therapies.

The NTM market in the US, the UK, and Japan was valued at $8.59 Billion in 2021. The market is projected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $11.04 Billion by 2031.